Therma Bright Inc Stock Price, News & Analysis

Therma Bright (OTCQB: TBRIF) received a follow-on order of 200 Venowave™ VW5 units from Texas distributor Gen-X Med on January 20, 2026. The shipment expands a distribution relationship after an initial rollout and targets post-surgical recovery for specialized knee procedures among top-tier orthopedic surgeons in the U.S. Gen-X Med cites patient and provider preference for mobile, at-home compression vs. tethered devices. The release cites industry data showing the global compression therapy market was $4.18B in 2024 and is projected to reach $6.72B by 2033 (CAGR 7.30%).

Therma Bright (OTCQB: TBRIF) reports progress at investee InStatin through Dec 18, 2025: the company has designated COPD as its lead clinical indication while retaining asthma in development plans, advanced a new lead molecule INS-102 with improved pharmacokinetics and longer lung residence in preclinical PK studies, and filed a provisional patent on novel inhaled statin formulations.

InStatin strengthened its team and advisory board, is pursuing a $35 million funding round in 2026 to reach proof-of-concept, and is engaging partners for inhaled delivery development with deferred payments pending funding.

Therma Bright (OTCQB: TBRIF) announced on October 10, 2025 the appointment of Michael Raimondo to its Board of Directors, elevating him from the advisory board. Raimondo is a 30-year US healthcare sales and operations veteran who the company says has led over $500 million in sales contracts and held senior commercial roles at Abbott.

Raimondo currently serves as Commercial Lead for Delphine Diagnostics and as Managing Partner at The Potentia Group; he said his focus will be building an internal sales team and expanding reseller channels to accelerate sales of Venowave, Therma Bright's flagship medical device. The company also announced the resignation of board member Alex Saringer.

Therma Bright (OTCQB:TBRIF) has expanded its strategic partnership with Gen-X Med for the distribution of Venowave™ VW5 devices. This follows an initial 200-unit sale announced in April 2025, targeting specialized knee surgeons in the U.S. healthcare network.

The partnership focuses on the growing specialized knee surgery market segment, with Gen-X Med reporting positive patient outcomes from the initial deployment. The global compression therapy market, valued at $4.18 billion in 2024, is projected to reach $6.72 billion by 2033, growing at a CAGR of 7.30%.

Therma Bright (OTCQB: TBRIF) has announced plans to amend the exercise price of 6,250,000 post-consolidation common share purchase warrants. The company proposes to reduce the exercise price from $0.80 to $0.06 per share for warrants issued during a Private Placement in June 2024.

Of the total warrants, 1,162,500 are held by company insiders, but due to TSXV policies, only 625,000 insider-held warrants will be eligible for repricing. The warrants maintain their original expiry dates of June 10 and June 20, 2027. Additionally, the company has received approval to postpone its 2025 annual general meeting to November 2025.

Therma Bright (OTCQB: TBRIF) has announced a significant 1:8 share consolidation effective July 8, 2025. The company's outstanding shares will be reduced from 454,457,147 to approximately 56,807,143 shares post-consolidation.

The consolidation will affect all outstanding incentive stock options and warrants, which will be adjusted proportionally. Shareholders will receive new share certificates or Direct Registration Advice after submitting their pre-consolidation certificates with a letter of transmittal to Olympia Trust Company.

Therma Bright Inc. (TBRIF) has announced plans for an 8:1 share consolidation, pending TSX Venture Exchange approval. The consolidation will reduce the company's outstanding shares from 451,632,147 to approximately 56,454,018 shares. This strategic move aims to provide increased flexibility for future financings and business transactions. The consolidation will also proportionally adjust outstanding options, warrants, and other rights to acquire common shares. The Board of Directors approved this action under the company's Articles of Incorporation, which allows for consolidations up to 10:1 without shareholder approval. Therma Bright confirms this is their only consolidation in the past 24 months, complying with TSXV Policy 5.8.

Therma Bright (TBRIF) announced plans to amend the exercise price of 42,725,000 outstanding warrants from its June 2024 private placement, subject to TSXV approval. The warrants' exercise price will be modified to $0.05 per share until December 31, 2025, and $0.10 thereafter, with expiration remaining June 10, 2027. Of the total warrants, 8,750,000 are held by insiders, but due to TSXV policies, only 4,272,500 insider-held warrants can be repriced. Additionally, the company plans to settle $124,000 in debt through the issuance of 6,200,000 common shares at $0.02 per share, pending TSXV approval.

Therma Bright Inc. (TBRIF) reports significant progress in its InStatin subsidiary, which focuses on developing inhaled statin therapies for respiratory conditions. The company announced the appointment of Professor Sir Peter Barnes, a globally recognized respiratory expert, as a strategic advisor. Key developments include: (1) Completion of a rodent pharmacokinetic study to determine lung exposure duration with selected statins, (2) Dr. Amir Zeki receiving an NIH grant for conducting statin efficacy studies in monkeys using an ozone sensitization model, and (3) Engagement of Mike Rafa for IP development. InStatin's strategic focus on mild to moderate asthma treatment suggests a potentially faster regulatory approval pathway compared to the COPD market.